Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP887026.RA9_jPLNppHIl66O-NtyzRBCdJwtqV3QzjsPq4ExfJnEk130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP887026.RA9_jPLNppHIl66O-NtyzRBCdJwtqV3QzjsPq4ExfJnEk130_assertion type Assertion NP887026.RA9_jPLNppHIl66O-NtyzRBCdJwtqV3QzjsPq4ExfJnEk130_head.
- NP887026.RA9_jPLNppHIl66O-NtyzRBCdJwtqV3QzjsPq4ExfJnEk130_assertion description "[Challenge experiments showed that co-administration of pVAX-IL-21-IL-15 and pVAX-CDPK1 significantly (P < 0.05) increased survival time (19.2 � 5.1 days) compared with pVAX-CDPK1 (17.3 � 4.3 days) or pVAX-IL-21-IL-15 (12.0 � 2.0 days) alone, and pVAX-IL-21-IL-15 +?pVAX-CDPK1 significantly reduced the number of brain cysts (72.7%) in contrast to pVAX-ROP13 (45.7%) or pVAX-IL-21-IL-15 alone (43.6%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP887026.RA9_jPLNppHIl66O-NtyzRBCdJwtqV3QzjsPq4ExfJnEk130_provenance.
- NP887026.RA9_jPLNppHIl66O-NtyzRBCdJwtqV3QzjsPq4ExfJnEk130_assertion evidence source_evidence_literature NP887026.RA9_jPLNppHIl66O-NtyzRBCdJwtqV3QzjsPq4ExfJnEk130_provenance.
- NP887026.RA9_jPLNppHIl66O-NtyzRBCdJwtqV3QzjsPq4ExfJnEk130_assertion SIO_000772 25192845 NP887026.RA9_jPLNppHIl66O-NtyzRBCdJwtqV3QzjsPq4ExfJnEk130_provenance.
- NP887026.RA9_jPLNppHIl66O-NtyzRBCdJwtqV3QzjsPq4ExfJnEk130_assertion wasDerivedFrom befree-20150227 NP887026.RA9_jPLNppHIl66O-NtyzRBCdJwtqV3QzjsPq4ExfJnEk130_provenance.
- NP887026.RA9_jPLNppHIl66O-NtyzRBCdJwtqV3QzjsPq4ExfJnEk130_assertion wasGeneratedBy ECO_0000203 NP887026.RA9_jPLNppHIl66O-NtyzRBCdJwtqV3QzjsPq4ExfJnEk130_provenance.